AGR2 and breast carcinoma: The close interplay between the UPR and the TNF pathway, plus recent findings that show that TNF-alpha can prevent in vivo breast cancer development, suggest that downregulation of the TNF pathway in AGR2-overexpressing breast cancers may contribute to their hormone therapy resistance [69].